Drugs / Aspirin
Aspirin
English name Acetylsalicylic Acid
also known as
acetylsalicylic acid · ASA · BAYe4465 · BAY1019036 · Acetylsalicylic acid (ASA) · Astrix · LDA · Aspirin Enteric-coated Tablets · +62 more
Small molecule targets CDX2, PTGS1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | DuoPlavin | — | 2010-03-14 | europa.eu ↗ |
| Approved | US (FDA) | PERCODAN | — | 1950-04-12 | fda.gov ↗ |
Trials 600 · started per year
today
US approved 1950
EU approved 2010
1
2
1
2
1
1
3
2
3
1
1
4
1
6
14
11
11
16
16
16
19
20
19
22
18
24
22
37
26
29
38
30
34
27
38
29
24
25
4
1
194819491950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 034 trials · 1 missed | ||||||
| Phase 0 | NCT03590821 | Dec 2027 → Jan 2028 expected | — | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07525635 | Apr 2026 → Aug 2027 expected | preeclampsia | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 0 | NCT07205250 | Feb 2026 → Jan 2028 expected | aortic disorder | The General Hospital of Western Theater Command | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06933056 | Sep 2025 → Sep 2026 overdue | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 0 | NCT06378398 | Jun 2024 → Feb 2026 | colorectal neoplasm | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT06383650 | Jun 2024 → May 2025 | arterial disorder, vascular brain injury | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 0 | NCT06168461 | Nov 2023 → Jun 2026 overdue | preeclampsia | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05709483 | Apr 2023 → Nov 2026 expected | preeclampsia | Rockefeller University | Recruiting | No outcome recorded |
| Phase 0 | NCT05308030 | Aug 2022 → May 2023 | peripheral arterial disease | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT05056896 | Jun 2022 → Nov 2024 overdue | colorectal cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05080946 | Nov 2021 → Nov 2026 | fallopian tube carcinoma, ovarian carcinoma, peritoneal carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
| Phase 0 | NCT05105919 | Aug 2021 → Apr 2024 overdue | type 2 diabetes mellitus | Montreal Heart Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04822363 | Aug 2021 → May 2025 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04284397 | Dec 2020 → Feb 2027 expected | — | Penn State University | Recruiting | No outcome recorded |
| Phase 0 | NCT04243278 | Sep 2020 → Dec 2022 | severe pre-eclampsia | Dr. Graeme Smith | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT04464070 | Aug 2020 → Jul 2027 expected | — | Vanderbilt University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT04083950 | Dec 2019 → Jan 2022 overdue | typhoid fever | USDA, Western Human Nutrition Research Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03765619 | Jun → Nov 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT03900871 | Apr 2019 → Apr 2020 | — | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03771651 | Mar 2019 → May 2022 overdue | fallopian tube cancer, salpingitis | University of Oklahoma | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03377543 | Jun 2018 → Dec 2025 overdue | inflammatory disease | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03378297 | May 2018 → Jan 2023 | ovarian cancer | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03100123 | Nov 2017 → Oct 2019 | antiphospholipid syndrome, pregnancy disorder with abortive outcome | Ottawa Hospital Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03051646 | Jan → May 2017 | — | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT02047539 | Jan 2015 → Mar 2021 | early-onset schizophrenia | Yale University | Terminated | No outcome recorded |
| Phase 0 | NCT02285738 | Dec 2014 → Jul 2017 | cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02268565 | Oct 2014 → Oct 2016 | insomnia | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT01817400 | Mar 2013 → Dec 2014 | female infertility, obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 0 | NCT01796951 | Feb 2013 → Feb 2016 | nicotine dependence | Vanderbilt University | Completed | No outcome recorded |
| Phase 0 | NCT01707823 | Oct 2012 → Jun 2018 | lung adenocarcinoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT00727948 | Jul 2008 → Dec 2010 | breast cancer | University of Vermont | Completed | No outcome recorded |
| Phase 0 | NCT00688961 | Jun → Aug 2007 | — | Sanford Research | Completed | No outcome recorded |
| Phase 0 | NCT00753935 | Jun 2006 → Aug 2011 | coronary artery disorder | Vanderbilt University | Completed | Missed primary |
| Phase 0 | NCT05428072 | Jan 2003 → Mar 2015 | alcoholic liver disease | Rush University Medical Center | Completed | No outcome recorded |
| Phase 161 trials · 2 met primary | ||||||
| Phase 1 | NCT07853248 | Oct 2026 → Jan 2027 expected | — | HK inno.N Corporation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07652723 | May → Dec 2026 expected | — | Bayer | Recruiting | No outcome recorded |
| Phase 1 | NCT07265466 | Nov 2025 → Mar 2026 overdue | — | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07323680 | Jun → Jul 2025 | — | Rhoshan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT06655194 | Feb → Apr 2025 | platelet aggregation, spontaneous | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT07444164 | Jan 2025 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT06444178 | Sep 2024 → Apr 2025 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06277609 | Feb → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05702463 | Jun 2023 → Jun 2027 expected | aspirin resistance, platelet aggregation, spontaneous, type 2 diabetes mellitus | Montreal Heart Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05625347 | Mar → Jun 2023 | obstructive lung disease, restrictive pulmonary disease | Vectura Limited | Terminated | No outcome recorded |
| Phase 1 | NCT05699070 | Feb → Apr 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05625334 | Oct 2022 → Mar 2023 | — | Vectura Limited | Completed | No outcome recorded |
| Phase 1 | NCT05304845 | Mar → May 2022 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT05166096 | Dec 2021 → May 2022 | — | Rhoshan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT04809818 | Mar → Aug 2021 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04792723 | Mar → Jul 2021 | cardiovascular disorder | Vita Green Health Products Co. Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04328883 | Jul → Oct 2019 | platelet aggregation, spontaneous | Inova Health Care Services | Completed | No outcome recorded |
| Phase 1 | NCT03728179 | Jan 2019 → Oct 2023 | cancer | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT03698513 | Oct 2018 → Feb 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03245489 | Mar 2018 → Nov 2023 | head and neck cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT04976465 | Jan 2018 → Jul 2025 overdue | pregnancy disorder, systemic lupus erythematosus | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 1 | NCT03341390 | Oct → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03225352 | Aug → Oct 2017 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02554721 | Aug 2015 → Mar 2018 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02370680 | Feb → Jul 2015 | cardiovascular disorder | New Haven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02229461 | Feb → May 2015 | hematologic disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02080858 | May → Oct 2014 | acute coronary syndrome, atrial fibrillation | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT01847404 | May → Jun 2013 | peptic ulcer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02060396 | Apr → Jun 2013 | — | Aragon Institute of Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01768637 | Jan 2013 → Apr 2014 | chronic kidney disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01708369 | Feb → May 2012 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 1 | NCT01448031 | Nov 2011 → Apr 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01710072 | Aug 2011 → Aug 2014 | — | University of Iowa | Completed | No outcome recorded |
| Phase 1 | NCT01281111 | Feb → Mar 2011 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01663038 | Dec 2010 → Jan 2011 | coronary artery disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01210339 | Nov 2010 → Aug 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01244100 | Oct → Dec 2010 | — | PLx Pharma | Completed | Met primary |
| Phase 1 | NCT01108588 | Jun → Aug 2010 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01238185 | Feb 2010 → Oct 2011 | preneoplastic lesion | Institute of Head and Neck Studies and Education, United Kingdom | Completed | No outcome recorded |
| Phase 1 | NCT01081353 | Feb → Mar 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01072604 | Jul → Aug 2009 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01409616 | Apr → Sep 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT04008979 | Feb → Jun 2008 | — | PLx Pharma | Completed | Met primary |
| Phase 1 | NCT00632086 | Feb 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT01424332 | Dec 2007 → Mar 2008 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00417898 | Mar 2007 → Dec 2012 | ischemic stroke | Hadassah Medical Organization | Withdrawn | No outcome recorded |
| Phase 1 | NCT00441519 | Feb → Apr 2007 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00425074 | Jan → Jun 2007 | cardiovascular disorder | Rottapharm Spain | Completed | No outcome recorded |
| Phase 1 | NCT00442052 | Nov 2006 → Jan 2007 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00566904 | Sep 2006 → Aug 2008 | postherpetic neuralgia | Biomedical Development Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00363753 | Aug 2006 → Mar 2007 | aspirin resistance, transient ischemic attack | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT00587496 | Apr 2006 → Jul 2008 | herpes simplex infectious disease | National Eye Institute (NEI) | Unknown | No outcome recorded |
| Phase 1 | NCT00265408 | Dec 2005 → Mar 2007 | ischemic stroke | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT00731302 | Apr 2005 → Apr 2017 | systemic lupus erythematosus | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00178464 | Mar 2005 → Apr 2009 | sickle cell disease | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT00948987 | Sep 2004 → Oct 2009 | aspirin resistance | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT02262793 | May → Jul 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02187562 | Jul → Aug 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT02268773 | Jan → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02278302 | Aug 1999 → Mar 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/27 trials · 2 met primary | ||||||
| Phase 1/2 | NCT06417411 | Mar 2024 → Mar 2026 overdue | preeclampsia, sickle cell disease | Instituto Nacional de Investigacao em Saude, Angola | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04645004 | Dec 2020 → Jan 2024 | preeclampsia | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT04031729 | Sep 2019 → Feb 2023 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Massachusetts General Hospital | Completed | Met primary |
| Phase 1/2 | NCT02401269 | Apr 2015 → Jan 2016 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1/2 | NCT00872534 | Jan → Jul 2009 | gastrointestinal mucositis | PLx Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT00771914 | Nov 2008 → Jan 2009 | — | University of Rochester | Completed | Met primary |
| Phase 1/2 | NCT00174902 | Oct 2003 → Aug 2004 | arteriosclerosis disorder | Swiss Federal Institute of Technology | Unknown | No outcome recorded |
| Phase 289 trials · 2 met primary · 18 missed | ||||||
| Phase 2 | NCT07663825 | Sep 2026 → Sep 2030 expected | congenital vascular malformation | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07661459 | Jun 2026 → Jul 2027 expected | cancer | Val Adams | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06866964 | Aug 2025 → Aug 2029 expected | germ cell tumor, testicular cancer | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06728072 | Mar 2025 → Jul 2035 expected | colorectal cancer | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 2 | NCT06554535 | Oct 2024 → Oct 2026 expected | small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06531525 | Aug 2024 → Dec 2026 expected | pregnancy disorder, protein S deficiency | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06425133 | Jul 2024 → Sep 2027 expected | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2 | NCT05775965 | May 2024 → Mar 2027 expected | — | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT05637567 | Apr 2024 → Sep 2028 expected | pancreas disorder | German Cancer Research Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05567562 | Mar 2024 → Feb 2025 | pulmonary emphysema | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 2 | NCT06228820 | Jan → Dec 2024 | platelet disorder, undefined | The University of The West Indies | Completed | No outcome recorded |
| Phase 2 | NCT04188119 | Dec 2023 → Sep 2024 | breast cancer | The Christie NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 2 | NCT06018688 | Sep 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05924971 | Jul 2023 → Dec 2026 expected | severe pre-eclampsia | MemorialCare Health System | Recruiting | No outcome recorded |
| Phase 2 | NCT06254391 | Jul 2023 → Jul 2025 | acute coronary syndrome, myocardial infarction | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 2 | NCT05557877 | Mar 2023 → Jul 2027 expected | breast carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT04912505 | Jan 2023 → Jan 2024 | thrombocytopenic purpura | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT05546320 | Oct 2022 → Mar 2025 | migraine disorder, patent foramen ovale | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05402124 | Jul 2022 → Mar 2023 | adenomatous colon polyp, colorectal cancer | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT05093790 | Mar → Nov 2022 | coronary artery disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04824911 | Mar 2021 → Feb 2025 | stroke disorder | Chang Gung Memorial Hospital | Completed | Met primary |
| Phase 2 | NCT04575519 | Mar 2021 → Dec 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Germans Trias i Pujol Research Institute | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04295486 | Mar 2021 → Mar 2027 expected | venous thromboembolism | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT05775536 | Jan → Nov 2021 | dry eye syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT04534218 | Oct 2020 → Dec 2023 | colorectal cancer, metastatic malignant neoplasm | Centre Hospitalier Universitaire de Besancon | Completed | Missed primary |
| Phase 2 | NCT04402385 | Aug 2020 → Jun 2022 | hypertensive urgency, preeclampsia | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04466670 | Jul 2020 → Dec 2021 | COVID-19 | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04363840 | May → Dec 2020 | COVID-19, disseminated intravascular coagulation, vitamin D deficiency | Louisiana State University Health Sciences Center in New Orleans | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04128956 | Mar 2020 → Feb 2024 | venous thromboembolism | University of Zurich | Terminated | Missed primary |
| Phase 2 | NCT05525156 | Mar 2020 → Jun 2022 | HIV infectious disease, cardiovascular disorder | Muhimbili University of Health and Allied Sciences | Suspended | Missed primary |
| Phase 2 | NCT03899987 | Nov 2019 → Apr 2027 expected | prostate adenocarcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03661463 | Oct → Dec 2019 | brain aneurysm | University Hospital Southampton NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT04038489 | Oct 2019 → Apr 2023 | estrogen-receptor positive breast cancer | University of Virginia | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03794596 | Sep 2019 → Feb 2021 | breast cancer | The Christie NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 2 | NCT04066725 | Jul 2019 → Mar 2021 | cutaneous melanoma | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT03654105 | Jul 2019 → Dec 2024 overdue | lung cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03927313 | Jun 2019 → Mar 2021 | HIV infectious disease, meningeal tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 2 | NCT03957902 | May 2019 → May 2025 overdue | colorectal cancer | Aragon Health Research Institute (IISAragon) | Recruiting | No outcome recorded |
| Phase 2 | NCT03893630 | Apr 2019 → Jul 2022 | preeclampsia | John O'Brien, MD | Completed | No outcome recorded |
| Phase 2 | NCT03329599 | Feb 2019 → Dec 2021 | atherosclerosis | Northern California Institute of Research and Education | Completed | Missed primary |
| Phase 2 | NCT04184921 | Jan 2019 → Jun 2023 | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03606642 | Nov 2018 → Dec 2021 | atherosclerosis, coronary artery disorder | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03638297 | Aug 2018 → Aug 2022 | colorectal cancer | Sun Yat-sen University | Unknown | Met primary |
| Phase 2 | NCT03079999 | Jun 2018 → Aug 2026 overdue | NF2-related schwannomatosis, acoustic neuroma | Massachusetts Eye and Ear Infirmary | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03396952 | Apr 2018 → Apr 2020 | cutaneous melanoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02965703 | Jan 2018 → Jan 2023 overdue | colorectal adenoma, colorectal carcinoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 2 | NCT03290820 | Jan 2018 → Sep 2024 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03543683 | Jan 2018 → Jan 2023 | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03170115 | Nov 2017 → Jan 2020 | rectum adenocarcinoma | Brazilian National Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03356769 | Nov 2017 → Nov 2021 | cognitive disorder, epilepsy, skin disorder, tuberous sclerosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02901067 | Feb 2017 → May 2021 | venous thromboembolism | Denver Health and Hospital Authority | Terminated | No outcome recorded |
| Phase 2 | NCT02659384 | Dec 2016 → Jun 2021 | ovarian neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT04062032 | Sep 2016 → Feb 2019 | cutaneous melanoma | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT02791958 | Mar 2016 → Oct 2017 | hypertensive disorder | Ferrer Internacional S.A. | Unknown | No outcome recorded |
| Phase 2 | NCT02521285 | Jan 2016 → Jun 2019 overdue | Barrett esophagus, esophageal adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 2 | NCT02348203 | Jan 2016 → Feb 2019 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02602938 | Nov 2015 → Nov 2016 | — | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03487406 | Sep 2015 → Nov 2017 | chronic obstructive pulmonary disease | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT02333123 | Jul 2015 → Aug 2016 | ulcer of lower limbs | St George's, University of London | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02420652 | Jun 2015 → Dec 2019 | prostate carcinoma | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02326350 | Feb 2015 → Nov 2018 | adult acute respiratory distress syndrome | Belfast Health and Social Care Trust | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02169271 | Nov 2014 → Jul 2018 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02227368 | Oct 2014 → May 2016 | peripheral arterial disease | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT02237365 | Oct 2014 → Jun 2016 | meningeal tuberculosis | Oxford University Clinical Research Unit, Vietnam | Completed | Missed primary |
| Phase 2 | NCT02565693 | Sep 2014 → Jan 2021 | atrial fibrillation, intracerebral hemorrhage | UMC Utrecht | Completed | Missed primary |
| Phase 2 | NCT02123849 | Jun 2014 → Sep 2016 | lung carcinoma, nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02285751 | Nov 2012 → Jul 2020 | critical illness polyneuropathy | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01616615 | Sep 2012 → Apr 2015 | placental insufficiency | Sara Varea | Completed | No outcome recorded |
| Phase 2 | NCT01504867 | Jan 2012 → Sep 2015 | acute respiratory distress syndrome | Mayo Clinic | Completed | Missed primary |
| Phase 2 | NCT01618006 | Jan 2012 → Apr 2013 | postoperative ventricular dysfunction | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01431053 | Jul 2011 → Jul 2014 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01005290 | Oct 2009 → Oct 2010 | hypertensive disorder | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT01004705 | Sep 2009 → Mar 2011 | low density lipoprotein cholesterol, mild elevation of | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00983580 | Aug 2009 → Oct 2016 | adenomatous colon polyp | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00567307 | Jan → Dec 2009 | cardiovascular disorder | Wake Forest University Health Sciences | Completed | Missed primary |
| Phase 2 | NCT00861341 | Dec 2008 → Jun 2010 | blood platelet disease, diabetes mellitus | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00578721 | Sep 2008 → Nov 2013 | colorectal cancer | University of California, Irvine | Completed | Missed primary |
| Phase 2 | NCT00623779 | Oct 2007 → Oct 2008 | persistent atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00474903 | Apr 2007 → Mar 2011 | Barrett esophagus, esophageal cancer | National Cancer Institute (NCI) | Completed | Mixed |
| Phase 2 | NCT00468910 | Mar 2007 → Dec 2009 | colon carcinoma, precancerous condition, rectal cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00603590 | Nov 2006 → Jun 2008 | heart disorder, hyperlipidemia, hypertensive disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00263211 | Jan 2006 → Sep 2009 | breast cancer | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01227629 | Sep 2003 → Nov 2004 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00406991 | Jun 2003 → Mar 2006 | diabetes mellitus, diabetic retinopathy | Schepens Eye Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00405613 | May 2003 → Dec 2005 | hemorrhagic disease | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00054938 | Mar 2003 → Dec 2005 | systemic lupus erythematosus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00105209 | Apr 2002 → Dec 2003 | pulmonary arterial hypertension | Kawut, Steven, MD | Completed | No outcome recorded |
| Phase 2 | NCT00020189 | Jun 2000 → Aug 2004 | head and neck cancer, thrombotic disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00000527 | Aug 1986 → Nov 1998 | carotid stenosis, heart disorder | Emory University | Completed | No outcome recorded |
| Phase 2/322 trials · 1 met primary · 3 missed | ||||||
| Phase 2/3 | NCT07337655 | Oct 2026 → Sep 2030 expected | — | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06068439 | Jan 2024 → Jan 2027 expected | diabetic kidney disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05865548 | May 2023 → Aug 2024 | oral cavity cancer | Banaras Hindu University | Completed | No outcome recorded |
| Phase 2/3 | NCT05462613 | May 2023 → Nov 2029 expected | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05568147 | Oct 2022 → Sep 2027 expected | thrombotic thrombocytopenic purpura | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04802785 | Jun → Jul 2021 | — | Dinara Zhumanbayeva | Unknown | No outcome recorded |
| Phase 2/3 | NCT04768179 | Feb → Jun 2021 | COVID-19 | Makerere University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04491695 | Sep 2020 → Dec 2022 | stroke disorder | Capital Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04365309 | Feb → Apr 2020 | COVID-19 | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03961360 | May 2019 → Apr 2023 | obesity disorder, preeclampsia | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2/3 | NCT03491410 | Jun 2018 → Dec 2019 | breast cancer | Centro Hospitalar Lisboa Ocidental | Unknown | No outcome recorded |
| Phase 2/3 | NCT03326791 | Dec 2017 → Feb 2022 overdue | metastasis from malignant tumor of colon | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02685748 | Jul 2017 → Dec 2019 | schizophrenia | Clinic for Psychiatric Disorders, Dr Laza Lazarevic | Completed | Missed primary |
| Phase 2/3 | NCT03093246 | May 2017 → Oct 2018 | periodontitis, aggressive | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT03093207 | May 2017 → Oct 2018 | periodontitis, aggressive, residual stage angle-closure glaucoma | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT03103152 | Dec 2016 → Mar 2020 | prostate cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2/3 | NCT02482857 | Dec 2011 → Jul 2015 | coronary artery disorder | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01012349 | Feb → May 2011 | — | Azidus Brasil | Unknown | No outcome recorded |
| Phase 2/3 | NCT00501254 | Feb 2005 → Feb 2007 | cardiovascular disorder | Rottapharm Spain | Completed | No outcome recorded |
| Phase 2/3 | NCT00222677 | May 2004 → Jan 2012 | atherosclerosis, pulmonary embolism, vein disorder, venous thromboembolism | University Of Perugia | Unknown | Met primary |
| Phase 2/3 | NCT00201461 | Jun 2003 → Apr 2010 | patent foramen ovale, transient ischemic attack | NMT Medical | Unknown | Missed primary |
| Phase 2/3 | NCT00272324 | Feb 1992 → Jan 2007 | colon adenoma, colorectal cancer, polyp of colon | Dartmouth-Hitchcock Medical Center | Completed | Missed primary |
| Phase 3129 trials · 9 met primary · 23 missed | ||||||
| Phase 3 | NCT06774846 | Jul 2028 → Oct 2031 expected | pneumonia | Centre Hospitalier Universitaire Dijon | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07524335 | Jul 2026 → Jul 2027 expected | atherosclerotic cardiovascular disease, coronary artery disorder | Montreal Heart Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07665853 | Jul 2026 → May 2028 expected | preeclampsia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07113158 | Apr 2026 → Apr 2029 expected | sudden sensorineural hearing loss | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05963568 | Apr 2026 → Jan 2029 expected | stroke disorder | Northern California Institute of Research and Education | Recruiting | No outcome recorded |
| Phase 3 | NCT06980025 | Jul 2025 → Dec 2028 expected | obstetric disorder | The George Washington University Biostatistics Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06930885 | Jun 2025 → May 2031 expected | atherosclerotic cardiovascular disease | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 3 | NCT06952712 | May 2025 → May 2028 expected | preeclampsia | FANG HE | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06494878 | Apr 2025 → Aug 2030 expected | venous thromboembolism | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06518317 | Nov 2024 → Nov 2028 expected | — | University Hospital, Caen | Recruiting | No outcome recorded |
| Show all 129 trials opens the full record — a long page | ||||||
| Phase 4155 trials · 11 met primary · 17 missed | ||||||
| Phase 4 | NCT07496281 | Mar 2027 → Feb 2032 expected | atrial fibrillation, coronary artery disorder | Ewha Womans University Mokdong Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07683923 | Mar 2027 → Feb 2033 expected | acute coronary syndrome, idiopathic spontaneous coronary artery dissection | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07854795 | Feb 2027 → Dec 2030 expected | coronary artery disorder | Vestre Viken Hospital Trust | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07602257 | Oct 2026 → Dec 2029 expected | — | Ottawa Heart Institute Research Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07281547 | Aug 2026 → Jun 2027 expected | endometrial carcinoma | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07431762 | Jun 2026 → Oct 2030 expected | cardiac valvular defect | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07642427 | Jun 2026 → May 2029 expected | acquired aneurysmal subarachnoid hemorrhage, brain ischemia | Ganzhou City People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644234 | Jun 2026 → Dec 2028 expected | transient ischemic attack | Sichuan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07563673 | May 2026 → Sep 2027 expected | cerebral infarction | Beijing Chao Yang Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07592507 | May 2026 → Feb 2032 expected | coronary artery disorder | Daejeon St. Mary's hospital | Not yet recruiting | No outcome recorded |
| Show all 155 trials opens the full record — a long page | ||||||
| Phase not applicable103 trials · 7 met primary · 3 missed | ||||||
| — | NCT07677410 | Jul 2026 → Jul 2029 expected | aortic valve insufficiency | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06937372 | Jul 2026 → Oct 2027 expected | venous thromboembolism | Queen Mary University of London | Recruiting | No outcome recorded |
| — | NCT07658989 | May 2026 → Jan 2030 expected | cardiac valvular defect, pregnancy disorder | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| — | NCT07846462 | Mar 2026 → Mar 2029 expected | acute coronary syndrome, coronary artery disorder | Jilin University | Recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06535568 | Jan 2026 → Jan 2028 expected | acute coronary syndrome, arterial occlusion, atherosclerosis, coronary stenosis | Fondazione Ricerca e Innovazione Cardiovascolare ETS | Recruiting | No outcome recorded |
| — | NCT07041385 | Nov 2025 → Jun 2027 expected | preeclampsia | Shalamar Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07240454 | Oct 2025 → Dec 2027 expected | — | Tao Liu | Recruiting | No outcome recorded |
| — | NCT07198529 | Sep 2025 → Sep 2029 expected | coronary artery disorder | Korea University Guro Hospital | Recruiting | No outcome recorded |
| — | NCT07852585 | Aug 2025 → Jun 2026 | preeclampsia | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT07066176 | Jul → Aug 2025 | — | Laval University | Completed | No outcome recorded |
| — | NCT07613840 | Apr 2025 → Apr 2027 expected | peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| — | NCT07673185 | Jan 2025 → Jul 2026 overdue | periodontitis | Al-Azhar University | Recruiting | No outcome recorded |
| — | NCT06276374 | Jul 2024 → Nov 2029 expected | carotid artery disorder | Woo-Keun Seo | Recruiting | No outcome recorded |
| — | NCT06108947 | Jan 2024 → Sep 2026 overdue | preeclampsia | St. Olavs Hospital | Active not recruiting | No outcome recorded |
| — | NCT05761704 | Nov 2023 → Nov 2024 | atrial fibrillation | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06185621 | Nov 2023 → Nov 2026 expected | aspirin resistance, recurrent acute pancreatitis | Air Force Military Medical University, China | Recruiting | No outcome recorded |
| — | NCT06058130 | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06053021 | Sep 2023 → Oct 2025 | ischemic stroke, thrombocytopenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05936606 | Aug 2023 → May 2027 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05580523 | Jul 2023 → Jan 2025 | preeclampsia | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT06261203 | Jul 2023 → Jul 2025 | preeclampsia | Egymedicalpedia | Unknown | No outcome recorded |
| — | NCT05825391 | May → Oct 2023 | brain aneurysm | Beijing Tiantan Hospital | Completed | Met primary |
| — | NCT07338331 | Apr 2023 → Apr 2025 | NAFLD1, type 2 diabetes mellitus | Galala University | Completed | No outcome recorded |
| — | NCT07523841 | Apr 2023 → Apr 2027 expected | periodontitis | Hanoi Medical University | Active not recruiting | No outcome recorded |
| — | NCT07087067 | Feb 2023 → Feb 2025 | preeclampsia | Galala University | Completed | Met primary |
| — | NCT05546957 | Jan → Apr 2023 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| — | NCT05419583 | Nov 2022 → Jun 2024 | myocardial infarction | University of Edinburgh | Completed | No outcome recorded |
| — | NCT05623904 | Oct 2022 → Dec 2025 | carotid stenosis | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT05353140 | Sep 2022 → Sep 2028 expected | atrial fibrillation | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT04694248 | Nov 2021 → Dec 2026 expected | May-Thurner syndrome, iliac vein thrombophlebitis, venous thromboembolism | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| — | NCT04971356 | Nov 2021 → Mar 2024 overdue | acute coronary syndrome | Xijing Hospital | Active not recruiting | Met primary |
| — | NCT05036109 | Oct 2021 → Feb 2026 | colon carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT04995159 | Sep 2021 → Jan 2026 overdue | coronary artery disorder | Lepu Medical Technology (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT05058924 | Aug 2021 → Feb 2024 | venous thromboembolism | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| — | NCT06442709 | Aug 2021 → Jul 2024 | nasopharyngeal carcinoma | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| — | NCT04820972 | May 2021 → Feb 2023 | intracerebral hemorrhage | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT05994287 | Jan 2021 → Jan 2022 | — | Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty | Completed | No outcome recorded |
| — | NCT04269863 | Nov 2020 → Nov 2021 | peripheral arterial disease | Unity Health Toronto | Unknown | No outcome recorded |
| — | NCT07597239 | Nov 2020 → Feb 2026 overdue | arterial occlusion, peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| — | NCT03821883 | Jun 2020 → Jun 2022 | atrial fibrillation, hemorrhagic disease, stroke disorder | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT04330729 | Apr 2020 → Dec 2026 expected | erythropoietin polycythemia | Zealand University Hospital | Recruiting | No outcome recorded |
| — | NCT04338919 | Apr 2020 → Apr 2021 | acute coronary syndrome | Fujian Medical University | Unknown | No outcome recorded |
| — | NCT04333407 | Apr 2020 → Nov 2021 | COVID-19 | Imperial College London | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04121611 | Oct 2019 → Oct 2021 | basilar artery occlusion | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| — | NCT03971500 | Aug 2019 → Oct 2023 overdue | coronary artery disorder | Nanjing First Hospital, Nanjing Medical University | Active not recruiting | Met primary |
| — | NCT04012268 | Jul 2019 → Nov 2020 | Moyamoya disease | Capital Medical University | Completed | No outcome recorded |
| — | NCT03797651 | Apr 2019 → Apr 2025 | acute coronary syndrome | Yonsei University | Unknown | Met primary |
| — | NCT03825757 | Jan 2019 → Jun 2023 | chronic rhinosinusitis | Sanna Salmi | Completed | No outcome recorded |
| — | NCT03450317 | Mar 2018 → Dec 2020 | — | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT03266731 | Jan 2018 → Jan 2019 | ischemic stroke | Assiut University | Unknown | No outcome recorded |
| — | NCT03318744 | Jan 2018 → Jul 2021 | brain infarction | First People's Hospital of Shenyang | Unknown | No outcome recorded |
| — | NCT03279809 | Oct 2017 → Sep 2020 | extrahepatic cholestasis | Woo Hyun Paik | Terminated | No outcome recorded |
| — | NCT03306550 | Oct 2017 → Apr 2018 | intermediate coronary syndrome | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| — | NCT03184805 | Jun 2017 → Apr 2018 | coronary artery disorder | Yonsei University | Terminated | No outcome recorded |
| — | NCT03023020 | Apr 2017 → Apr 2021 | bleeding disorder, vascular-type, coronary artery disorder | ECRI bv | Completed | Met primary |
| — | NCT03583229 | Oct 2016 → Oct 2021 | coronary artery disorder, platelet disorder, undefined | Aarhus University Hospital | Unknown | No outcome recorded |
| — | NCT02922673 | Sep → Dec 2016 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT05604118 | Aug 2016 → Aug 2018 | blood platelet disease | Cardiff University | Completed | No outcome recorded |
| — | NCT02921360 | Aug 2016 → Dec 2018 | brain ischemia, ischemic stroke | City Clinical Hospital No. 67, Moscow, Russia | Unknown | No outcome recorded |
| — | NCT02696226 | Feb 2016 → Jul 2017 | aortic valve disorder | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02084615 | Aug 2014 → Aug 2016 | — | Jesse Brown VA Medical Center | Unknown | No outcome recorded |
| — | NCT02209909 | Jul 2014 → Sep 2015 | coronary artery disorder | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02079077 | Apr 2014 → Dec 2015 | HIV infectious disease | University of Manitoba | Completed | No outcome recorded |
| — | NCT02079194 | Mar 2014 → Jul 2018 | coronary artery disorder | Samsung Medical Center | Unknown | Met primary |
| — | NCT04371874 | Jan 2014 → Jul 2017 | hypertensive disorder | First Affiliated Hospital Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT02359643 | May 2013 → Apr 2017 | Kawasaki disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT02802072 | Jan 2013 → Jan 2014 | carotid stenosis | Beijing Chao Yang Hospital | Completed | No outcome recorded |
| — | NCT01763606 | Dec 2012 → Apr 2019 | — | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01506505 | Jul 2012 → Jul 2013 | cerebrovascular disorder, peripheral arterial disease | UMC Utrecht | Completed | Mixed |
| — | NCT01465256 | Apr 2012 → Jun 2014 | — | Soonchunhyang University Hospital | Unknown | No outcome recorded |
| — | NCT01547390 | Mar 2012 → Jul 2015 | preeclampsia | Washington University School of Medicine | Terminated | Missed primary |
| — | NCT01096706 | Jul 2011 → Jan 2012 | heart disorder, vascular disorder | University of Edinburgh | Completed | No outcome recorded |
| — | NCT02744716 | May 2011 → Jan 2016 | adhesions of uterus | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| — | NCT01612247 | Feb 2011 → Feb 2013 | breast cancer | University of Vermont | Unknown | No outcome recorded |
| — | NCT01375400 | Dec 2010 → Jul 2011 | ischemic stroke | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| — | NCT01257893 | Nov 2010 → Oct 2011 | migraine disorder | Swedish Medical Center | Withdrawn | No outcome recorded |
| — | NCT01696760 | Oct 2010 → Dec 2012 | bone neoplasm, musculoskeletal system cancer, soft tissue sarcoma, venous thromboembolism | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT01264640 | Jul 2010 → Feb 2011 | — | University of Rostock | Unknown | No outcome recorded |
| — | NCT01050153 | Mar 2010 → Dec 2011 | venous thromboembolism | Denver Health and Hospital Authority | Completed | No outcome recorded |
| — | NCT01066923 | Feb 2010 → Jun 2011 | exercise-induced malignant hyperthermia | Dave Hostler | Completed | No outcome recorded |
| — | NCT00942617 | Jul 2009 → Jun 2012 | platelet aggregation, spontaneous | Vanderbilt University | Withdrawn | No outcome recorded Stop: Business |
| — | NCT00898222 | May → Aug 2009 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT02384070 | Jan 2009 → Dec 2013 | coronary artery disorder | Odessa Heart Institute | Completed | No outcome recorded |
| — | NCT01212302 | Oct 2008 → Mar 2010 | coronary artery disorder | Ruhr University of Bochum | Completed | No outcome recorded |
| — | NCT02823743 | Mar 2008 → Apr 2016 | habitual spontaneous abortion | Göteborg University | Completed | No outcome recorded |
| — | NCT00578760 | Feb 2008 → Feb 2010 | platinum-induced ototoxicity | University Health Network, Toronto | Unknown | No outcome recorded |
| — | NCT02261025 | Jan 2008 → Sep 2014 | — | Shanghai Jiao Tong University School of Medicine | Completed | Missed primary |
| — | NCT01361620 | Dec 2007 → Apr 2011 | blood platelet disease | George Washington University | Completed | No outcome recorded |
| — | NCT00563875 | Nov 2007 → Jun 2008 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT01061034 | Mar → Jun 2007 | — | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
| — | NCT00389129 | Nov 2006 → Mar 2007 | aspirin resistance | University of Aarhus | Completed | No outcome recorded |
| — | NCT00418860 | Sep 2006 → Apr 2008 | coronary artery disorder | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00536068 | Aug 2006 → Aug 2007 | vascular hemostatic disease | Kantonsspital Graubünden | Completed | No outcome recorded |
| — | NCT00518141 | Mar 2006 → May 2009 | — | Sykehuset Telemark | Completed | No outcome recorded |
| — | NCT00898950 | Aug 2004 → Jul 2006 | type 2 diabetes mellitus | University of Portsmouth | Completed | No outcome recorded |
| — | NCT00646906 | Jun 2004 → Jan 2012 | arthritic joint disease, myocardial infarction | University of Pennsylvania | Completed | Missed primary |
| — | NCT00494156 | Jul 2003 → Jul 2008 | arterial disorder | C. Clay Cothren, MD | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00153725 | Feb 2003 → Sep 2006 | cerebrovascular disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT00262275 | Jul 2002 → Jul 2004 | ischemic disease | Papworth Hospital NHS Foundation Trust | Completed | Mixed |
| — | NCT00033319 | May 1997 → ? | colorectal cancer | Queen's Medical Center | Unknown | No outcome recorded |
| — | NCT00382421 | Feb 1992 → Apr 2006 | myocardial ischemia | Luzerner Kantonsspital | Completed | No outcome recorded |
| Comparator or background therapy733 trials | ||||||
| Phase 0 | NCT07832578 Comparator | Jun → Dec 2026 expected | limb ischemia | King Edward Medical University | Recruiting | No outcome recorded |
| Phase 0 | NCT06339021 Background | Apr 2024 → Dec 2026 expected | ST-elevation myocardial infarction | Shenyang Northern Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04040465 Comparator | Feb → Oct 2021 | aspirin resistance | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04153760 Comparator | Oct 2020 → Sep 2023 | venous thromboembolism | University of Calgary | Completed | No outcome recorded |
| Phase 0 | NCT04535804 Comparator | Oct 2020 → Sep 2022 | adenomyosis | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| Show all 733 trials opens the full record — a long page | ||||||
Press releases naming this drug 33 releases
Evidence & citations 75 cited values
Every value below carries the sentence it was read from. 1,352 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aspirin | “patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with...” PMID 38599220 ↗ Apr 20241145“The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and...” NCT07658989 ↗ “Thromboprophylactic regimens Aspirin®(acetylsalicylic acid, AA, Bayer) 300mg/day or Xarelto® (rivaroxaban, factor Xa-inhibitor, Bayer) 10mg/day will be randomly(according to...” NCT02271399 ↗ “This is a research study to compare the efficacy of aspirin (acetylsalicylic acid) and pneumatic compression devices versus enoxaparin (also known as Lovenox) and pneumatic...” NCT01696760 ↗ “Eligible patients, who have a history or new onset paroxysmal, persistent, or permanent non-valvular AF, referred to the study centers with indications for PCI will be randomly...” PMID 26003433 ↗ May 2015 “Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary...” NCT02548650 ↗ “A total of 2268 STEMI patients indicated for primary PCI with current generation platinum‑chromium everolimus-eluting stents were randomized 1:1 to either prasugrel monotherapy...” PMID 41436299 ↗ Dec 2025 “Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors...” NCT03703635 ↗ “The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has...” NCT06535568 ↗ “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Participants were randomly assigned (1:1) to receive DAPT (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily) for 12 months or the same dual antiplatelet regimen for...” PMID 42120081 ↗ May 2026 |
| Known as | acetylsalicyclic acid | “Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio)” NCT02239120 ↗ |
| Known as | Acetylsalicylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01681615 ↗ |
| Known as | acetylsalicylic acid | “To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg...” NCT02262793 ↗240“The goal of this clinical trial is to compare the pharmacokinetics (PK) pharmacodynamics (PD), safety and tolerability of acetylsalicylic acid powder for oral inhalation...” NCT05625347 ↗ “An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and...” NCT01210339 ↗ “This study aims to evaluate the benefits of Acetylsalicylic acid (ASA) as an add-on treatment to local non-steroidal anti-inflammatory drug for the management of thrombotic...” NCT07663825 ↗ “Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and...” NCT01005290 ↗ “Open-label Randomized, Three-fold Cross-over, Single-center Interaction Study to Investigate the Influence of Multiple Doses of Acetylsalicylic Acid (ASA) (Aspirin) on the...” NCT07652723 ↗ “We investigated whether low-dose acetylsalicylic acid (ASA, aspirin) administration prior to and during exposure to an experimental sleep restriction challenge affects cellular...” PMID 41686719 ↗ Feb 2026 “Intervention group will discontinuate of Acetyl Salicylic acid at 24-28 weeks of gestation while Control Group will continue Acetyl Salicylic acid 150 mg/day until 36 weeks of...” NCT07665853 ↗ “Using the minimisation method in an online randomisation system, patients were randomly assigned (1:1) to receive 100 mg acetylsalicylic acid once per day in either the...” PMID 39577920 ↗ Dec 2024 “The present randomised controlled trial tests aspirin (acetylsalicylic acid (ASA)) as a convenient method to prevent overheating and improve exercise performance in persons with MS.” PMID 33191260 ↗ Nov 2020 “Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover” NCT02370680 ↗ |
| Known as | Acetylsalicylic acid (ASA) | “Acetylsalicylic acid (ASA)” NCT04575519 ↗ |
| Known as | Albyl-E | “Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)” NCT00789308 ↗ |
| Known as | ASA | “To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg...” NCT02262793 ↗94“Study 2: subjects received clopidogrel alone (75 mg/day for 9 days) and clopidogrel alone for 4 days followed by clopidogrel plus fixed-combination esomeprazole 20 mg/low-dose...” PMID 24677117 ↗ Jun 2014 “This study aims to evaluate the benefits of Acetylsalicylic acid (ASA) as an add-on treatment to local non-steroidal anti-inflammatory drug for the management of thrombotic...” NCT07663825 ↗ “Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on...” NCT03287167 ↗ “Open-label Randomized, Three-fold Cross-over, Single-center Interaction Study to Investigate the Influence of Multiple Doses of Acetylsalicylic Acid (ASA) (Aspirin) on the...” NCT07652723 ↗ “We investigated whether low-dose acetylsalicylic acid (ASA, aspirin) administration prior to and during exposure to an experimental sleep restriction challenge affects cellular...” PMID 41686719 ↗ Feb 2026 “Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized...” NCT00496769 ↗ “However, single anti-platelet therapy with acetylsalicylic acid (ASA) without clopidogrel has been reported to improve bleeding outcomes and a composite of bleeding and...” NCT05035277 ↗ “The present randomised controlled trial tests aspirin (acetylsalicylic acid (ASA)) as a convenient method to prevent overheating and improve exercise performance in persons with MS.” PMID 33191260 ↗ Nov 2020 “Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3).” NCT00486512 ↗ “Fifty patients with T2D and carotid atherosclerotic plaques were randomly assigned to either a 200 mg/d cilostazol (CTZ) group or a 100 mg/d aspirin (ASA) group for 6 months.” PMID 32700396 ↗ Sep 2020 |
| Known as | Ascriptin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | ASP | “Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy....” NCT04976465 ↗1“Aspirin (ASP), originally extracted from willow bark, is a small molecule compound with various effects such as antipyretic, anti-inflammatory, analgesic, and antiplatelet aggregation.” NCT06554535 ↗ |
| Known as | Aspegic | “Aspegic ® (Aspirin),100 mg/day” NCT00986765 ↗ |
| Known as | Aspir Low | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Aspir-Trin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Aspirin (ASA) | “Aspirin (ASA)” NCT01823510 ↗1“Aspirin (ASA)” NCT01642238 ↗ |
| Known as | Aspirin 325Mg Tab | “Aspirin 325Mg Tab, Aspirin 81Mg Tab” NCT05868525 ↗ |
| Known as | aspirin 81mg EC tab | “aspirin 81mg EC tab” NCT05567562 ↗ |
| Known as | Aspirin 81Mg Tab | “Aspirin 325Mg Tab, Aspirin 81Mg Tab” NCT05868525 ↗ |
| Known as | Aspirin cardio | “Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months” NCT04128956 ↗ |
| Known as | Aspirin Enteric-coated Tablets | “Aspirin Group: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg...” NCT06738992 ↗2“Aspirin Enteric-coated Tablets, 0.1g/d by mouth” NCT03176498 ↗ “Drug: Aspirin Enteric-Coated Tablets” NCT07378228 ↗ |
| Known as | aspirin lysine | “Provided with supply of aspirin (aspirin lysine) for periods 1, 2 and 3 (2 boxes of 30 sachets)” NCT04990791 ↗ |
| Known as | Aspirin protect | “Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months” NCT04128956 ↗ |
| Known as | Aspirin tablet | “Drug: Aspirin Tablet, 100 mg/d” NCT03186456 ↗ |
| Known as | Aspirin: acid acetylsalycilic | “Aspirin: acid acetylsalycilic” NCT00822536 ↗ |
| Known as | Aspirin: Aspirin Protect (Bayer) 100mg | “Aspirin: Aspirin Protect (Bayer) 100mg” NCT00947843 ↗ |
| Known as | Aspirin: Astrix | “Aspirin: Astrix” NCT01663038 ↗ |
| Known as | ASPIRINA | “A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered.” NCT05225961 ↗ |
| Known as | ASPIRINA JUNIOR | “A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)” NCT07444164 ↗ |
| Known as | Aspirtab | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Aspocid Paediatric | “Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))” NCT01051778 ↗ |
| Known as | asprin | “Patient will receive dual anti platelet asprin And clopidogrel” NCT03896321 ↗ |
| Known as | Asprine | “preoperative gargling of Asprine and Benzydamine HCL to study comparative effects on intensity and duration of POST.” NCT05343429 ↗ |
| Known as | ASS Genericon | “acetylsalicylic acid (ASS Genericon) 500mg” NCT06710600 ↗ |
| Known as | Astrix | “versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in healthy male volunteers.” NCT01657071 ↗3“Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)” NCT01388660 ↗ “Plavix (clopidogrel) and Astrix (aspirin)” NCT01422109 ↗ “Aspirin: Astrix” NCT01496261 ↗ |
| Known as | Baby aspirin | “Baby aspirin 81mg: Twice daily for 6 weeks after surgery” NCT04766996 ↗ |
| Known as | Bay Aspirin | “Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily.” NCT05902000 ↗ |
| Known as | BAY e4465A | “A Prospective, Randomized, Verum Controlled, Open Label, Parallel Group Multi-center Phase III Clinical Trial to Demonstrate the Superiority of 500 or 250 mg Aspirin® i.v. (BAY...” NCT00910065 ↗ |
| Known as | BAY1019036 | “Acetylsalicylic acid (Fast release Aspirin, BAY1019036)” NCT01117636 ↗5“Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo” NCT01453400 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT01072604 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT01552798 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT02313909 ↗ “Acetylsalicylic Acid (Aspirin BAY1019036)” NCT01081353 ↗ |
| Known as | BAYE004465 | “Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)” NCT06655194 ↗ |
| Known as | BAYe4465 | “Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain” NCT01361399 ↗11“500 mg acetylsalicylic acid (Aspirin, BAYE4465)” NCT03225352 ↗ “Aspirin (Acetylsalicylic acid, BAYe4465)” NCT02394093 ↗ “Aspirin (Acetylsalicylic acid, BAYE4465)” NCT01033526 ↗ “Aspirin (Acetylsalicylic acid, BAYE4465)” NCT00501059 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT00963443 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01072604 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT01117636 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT01028079 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01465009 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01464983 ↗ |
| Known as | Bayer | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)
Other Names:
Ecotrin,...” NCT01731236 ↗1“One EC aspirin (Bayer®) 81 mg tablet” NCT01557335 ↗ |
| Known as | Bayer Aspirin | “Aspirin Group: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg...” NCT06738992 ↗1“81mg of Bayer Aspirin per oral daily” NCT06228820 ↗ |
| Known as | Bayer Genuine Aspirin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Bufferin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Cardisprin 75 | “75 mg aspirin (Cardisprin 75, Cosmos, Nairobi, Kenya)” NCT05525156 ↗ |
| Known as | D,L-lysine acetylsalicylate | “D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV” NCT00910065 ↗ |
| Known as | Durlaza | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Ecotrin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Enteric Coated Aspirin Tablet | “Drug: Enteric Coated Aspirin Tablet” NCT04330872 ↗ |
| Known as | Enteric-coated Aspirin | “Arm I: Chemoprevention. Enteric-coated Aspirin, ASA, NSC-27223.” NCT00002527 ↗ |
| Known as | Fasprin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Fast release Aspirin | “Acetylsalicylic acid (Fast release Aspirin, BAY1019036)” NCT01117636 ↗ |
| Known as | Fixed dose combination of clopidogrel/Aspirin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01663038 ↗ |
| Known as | Genacote | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Halfprin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Hjertemagnyl | “EPO + ASA Treatment Aranesp treatment is supplemented with ASA (Hjertemagnyl ® 75 mg x 1 daily).” NCT04330729 ↗ |
| Known as | I-ASA | “The goal of this clinical trial is to compare the pharmacokinetics (PK) pharmacodynamics (PD), safety and tolerability of acetylsalicylic acid powder for oral inhalation...” NCT05625347 ↗ |
| Known as | IR-ASA | “We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA).” PMID 31420787 ↗ Nov 2019 |
| Known as | juspirin | “Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.” NCT04168398 ↗ |
| Known as | LD EC-ASA | “Bayer® low-dose enteric-coated aspirin 81 mg tablets (LD EC-ASA)” PMID 39008026 ↗ Jul 2024 |
| Known as | LD PL-ASA | “Vazalore® low-dose phospholipid-aspirin liquid-filled 81 mg capsules (LD PL-ASA)” PMID 39008026 ↗ Jul 2024 |
| Known as | LDA | “The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and...” NCT07658989 ↗3“The aim of the present randomized study was to determine whether TRUS-guided PB performed in patients continuing low-dose aspirin (LDA) is associated with a greater incidence,...” NCT02744937 ↗ “Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.” NCT05253781 ↗ “Anti-aggregation therapy, including treatment with low-dose aspirin (LDA) is an established risk factor for intracranial hemorrhage” NCT01470040 ↗ |
| Known as | LDASA | “Low-dose aspirin (LD-ASA) is commonly prescribed to prevent PE and confers a consistently positive effect on mitigating PE risk when given in early gestation to women at risk.” NCT04243278 ↗1“Administration of low-dose acetylsalicylic acid (LDASA) has shown to improve maternal and perinatal outcomes” NCT05073718 ↗ |
| Known as | Low-dose aspirin | “Low-dose aspirin (LD-ASA) is commonly prescribed to prevent PE and confers a consistently positive effect on mitigating PE risk when given in early gestation to women at risk.” NCT04243278 ↗1“Drug: Low-Dose Aspirin” NCT07281547 ↗ |
| Known as | Norwich Aspirin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | NSC-27223 | “Arm I: Chemoprevention. Enteric-coated Aspirin, ASA, NSC-27223.” NCT00002527 ↗ |
| Known as | PL2200 | “Patients were exposed to three 325-mg aspirin formulations: plain aspirin, PL2200 (a modified-release lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin.” PMID 28089180 ↗ Jan 20171“Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)” NCT02008942 ↗ |
| Known as | plain Aspirin | “Drug: Plain Aspirin” NCT04330872 ↗ |
| Known as | Trombyl | “Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)” NCT00789308 ↗ |
| Known as | UI1610477 | “Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)” NCT06655194 ↗ |
| Known as | UI1615160 | “Acetylsalicylic Acid (BAYE004465, UI1615160)” NCT06655194 ↗ |
| Known as | Vazalore Aspirin | “81mg Vazalore Aspirin per oral daily” NCT06228820 ↗ |
| Known as | VTS-Aspirin | “Patients were randomized to receive either 324 mg of VTS-Aspirin™ and 0.5 mg/kg of oral ketamine (AOK) that is directly swallowed or 0.5 mg/kg of oral ketamine (OK) alone that...” PMID 35777275 ↗ May 2022 |
| Action | Inhibit | “Aspirin, in small doses, inhibits platelet aggregation for prolonged periods of time” NCT00000491 ↗ |
| Modality | Small molecule | “a widely available and prototypical non-steroidal anti-inflammatory agent, aspirin” NCT01797575 ↗ |
| Route | Oral | “pre- and post-operative oral administration of platelet-inhibiting drugs” NCT00000527 ↗ |
| Target | PTGS1 | “Suboptimal inhibition of platelet cyclooxygenase 1 (COX-1) by aspirin” PMID 24022862 ↗ Feb 2014 |